Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis

In silico and in vivo evidences

Paolo Fagone, Emanuela Mazzon, Eugenio Cavalli, Alessia Bramanti, Maria Cristina Petralia, Katia Mangano, Yousef Al-Abed, Placido Bramanti, Ferdinando Nicoletti

Research output: Contribution to journalArticle

Abstract

Macrophage migration inhibitory factor (MIF) is a cytokine with pleiotropic actions involved in the pathogenesis of autoimmune disorders, including Multiple Sclerosis (MS). We have first evaluated in silico the involvement of MIF, its homologue D-DT, and the receptors CD74, CD44, CXCR2 and CXCR4 in encephalitogenic T cells from a mouse model of MS, the Experimental Allergic Encephalomyelitis (EAE), as well as in circulating T helper cells from MS patients. We show an upregulation of the receptors involved in MIF signaling both in the animal model and in patients. Also, a significant increase in MIF receptors is found in the CNS lesions associated to MS. Finally, the specific inhibitor of MIF, ISO-1, improved both ex vivo and in vivo the features of EAE. Overall, our data indicate that there is a significant involvement of the MIF pathway in MS ethiopathogenesis and that interventions specifically blocking MIF receptors may represent useful therapeutic approaches in the clinical setting.

Original languageEnglish
Pages (from-to)46-56
Number of pages11
JournalJournal of Neuroimmunology
Volume322
DOIs
Publication statusPublished - Sep 15 2018

Fingerprint

Macrophage Migration-Inhibitory Factors
Computer Simulation
Multiple Sclerosis
Cytokines
Autoimmune Experimental Encephalomyelitis
Helper-Inducer T-Lymphocytes
Up-Regulation
Animal Models
T-Lymphocytes

Cite this

Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis : In silico and in vivo evidences. / Fagone, Paolo; Mazzon, Emanuela; Cavalli, Eugenio; Bramanti, Alessia; Petralia, Maria Cristina; Mangano, Katia; Al-Abed, Yousef; Bramanti, Placido; Nicoletti, Ferdinando.

In: Journal of Neuroimmunology, Vol. 322, 15.09.2018, p. 46-56.

Research output: Contribution to journalArticle

@article{bfa5e78a160042a8bfe33caf265a04e7,
title = "Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences",
abstract = "Macrophage migration inhibitory factor (MIF) is a cytokine with pleiotropic actions involved in the pathogenesis of autoimmune disorders, including Multiple Sclerosis (MS). We have first evaluated in silico the involvement of MIF, its homologue D-DT, and the receptors CD74, CD44, CXCR2 and CXCR4 in encephalitogenic T cells from a mouse model of MS, the Experimental Allergic Encephalomyelitis (EAE), as well as in circulating T helper cells from MS patients. We show an upregulation of the receptors involved in MIF signaling both in the animal model and in patients. Also, a significant increase in MIF receptors is found in the CNS lesions associated to MS. Finally, the specific inhibitor of MIF, ISO-1, improved both ex vivo and in vivo the features of EAE. Overall, our data indicate that there is a significant involvement of the MIF pathway in MS ethiopathogenesis and that interventions specifically blocking MIF receptors may represent useful therapeutic approaches in the clinical setting.",
author = "Paolo Fagone and Emanuela Mazzon and Eugenio Cavalli and Alessia Bramanti and Petralia, {Maria Cristina} and Katia Mangano and Yousef Al-Abed and Placido Bramanti and Ferdinando Nicoletti",
note = "Copyright {\circledC} 2018 The Authors. Published by Elsevier B.V. All rights reserved.",
year = "2018",
month = "9",
day = "15",
doi = "10.1016/j.jneuroim.2018.06.009",
language = "English",
volume = "322",
pages = "46--56",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",

}

TY - JOUR

T1 - Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis

T2 - In silico and in vivo evidences

AU - Fagone, Paolo

AU - Mazzon, Emanuela

AU - Cavalli, Eugenio

AU - Bramanti, Alessia

AU - Petralia, Maria Cristina

AU - Mangano, Katia

AU - Al-Abed, Yousef

AU - Bramanti, Placido

AU - Nicoletti, Ferdinando

N1 - Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

PY - 2018/9/15

Y1 - 2018/9/15

N2 - Macrophage migration inhibitory factor (MIF) is a cytokine with pleiotropic actions involved in the pathogenesis of autoimmune disorders, including Multiple Sclerosis (MS). We have first evaluated in silico the involvement of MIF, its homologue D-DT, and the receptors CD74, CD44, CXCR2 and CXCR4 in encephalitogenic T cells from a mouse model of MS, the Experimental Allergic Encephalomyelitis (EAE), as well as in circulating T helper cells from MS patients. We show an upregulation of the receptors involved in MIF signaling both in the animal model and in patients. Also, a significant increase in MIF receptors is found in the CNS lesions associated to MS. Finally, the specific inhibitor of MIF, ISO-1, improved both ex vivo and in vivo the features of EAE. Overall, our data indicate that there is a significant involvement of the MIF pathway in MS ethiopathogenesis and that interventions specifically blocking MIF receptors may represent useful therapeutic approaches in the clinical setting.

AB - Macrophage migration inhibitory factor (MIF) is a cytokine with pleiotropic actions involved in the pathogenesis of autoimmune disorders, including Multiple Sclerosis (MS). We have first evaluated in silico the involvement of MIF, its homologue D-DT, and the receptors CD74, CD44, CXCR2 and CXCR4 in encephalitogenic T cells from a mouse model of MS, the Experimental Allergic Encephalomyelitis (EAE), as well as in circulating T helper cells from MS patients. We show an upregulation of the receptors involved in MIF signaling both in the animal model and in patients. Also, a significant increase in MIF receptors is found in the CNS lesions associated to MS. Finally, the specific inhibitor of MIF, ISO-1, improved both ex vivo and in vivo the features of EAE. Overall, our data indicate that there is a significant involvement of the MIF pathway in MS ethiopathogenesis and that interventions specifically blocking MIF receptors may represent useful therapeutic approaches in the clinical setting.

U2 - 10.1016/j.jneuroim.2018.06.009

DO - 10.1016/j.jneuroim.2018.06.009

M3 - Article

VL - 322

SP - 46

EP - 56

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -